Bopindolol is an orally active antagonist of β-adrenoceptors (ARs) with partial agonist activity. Bopindolol is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype. Bopindolol is a prodrug of pindolol and can be rapidly metabolized to an active hydrolyzed form. Bopindolol can be used for essential and renovascular hypertension research [1] [2].

Bopindolol (intravenous injection; l8, 16 and 32 μg/kg) dose-dependently inhibits isoprenaline-induced tachycardia, and this agent is 4 times more potent than propranolol in anaesthetised dogs [1]. Bopindolol (intraperitoneal injection; 3.0 mg/kg) reduces the diastolic blood pressure (DBP) in pithed rats. And pindolol (1.0 mg/kg) produces similar decreases in DBP of about 8 mmHg. it also produces a dose-dependent decrease in heart rate [2].